We recently discovered that dectin-1-activated dendritic cells (DCs) drive potent T helper (Th) 9 cell responses and antitumor immunity. However, the underlying mechanisms need to be further defined. The cytokine microenvironment is critical for Th cell differentiation. Here, we show that dectin-1 activation enhances interleukin (IL)-33 expression in DCs. We found that blocking IL-33/ST2 inhibits dectin-1-activated DC-induced Th9 cell differentiation. More importantly, the addition of IL-33 further promotes Th9 cell priming and antitumor efficacy induced by dectin-1-activated DCs. Mechanistically, in addition to the promotion of Th9 and Th1 cells, dectin-1-activated DCs combined with IL-33 abolish the activity of IL-33 in the induction of regulatory T cells. Furthermore, the combined treatment of dectin-1-activated DCs and IL-33 increases the frequencies of CD4 + T cells by fostering their proliferation and inhibiting their exhaustive differentiation. Thus, our results demonstrate the important role of IL-33 in dectin-1-activated DC-induced Th9 cell differentiation and antitumor efficacy, and suggest that the combination of dectin-1-activated DCs and IL-33 may present a new effective modality of DC-based vaccines in tumor immunotherapy.
through the activation of other effectors, such as tumor-specific CD8 + CTLs and mast cells (10, 11) . Th9 cells may also exert a direct antitumor activity at the tumor site (12, 13) . These findings suggest that strategies to preferably stimulate DC induction of Th9 cells may greatly improve the antitumor efficacy of DC-based tumor therapy.
The cytokine milieu is the most important determinant of the fate of T cell differentiation (5) . Th9 cells can be generated in vitro by culturing naïve CD4 + T cell with IL-4 and transforming growth factor β (TGF-β) (6, 7) . However, other cytokines, such as TL1A, OX40L, and IL-25, can also promote Th9 cell development (14) (15) (16) . In addition, multiple transcription factors, such as PU.1, IRF4, and Foxo1, are shown to be involved in Th9 cell differentiation (17) (18) (19) . Dectin-1 is a member of C-type lectinlike receptors that plays an important role in anti-fungal immune responses (20) (21) (22) . We recently found that DCs activated via dectin-1 trigger potent antitumor effects through the induction of Th9 cells (12, 13) . We further found that dectin-1 stimulates DCs to overexpress 42 cytokines and costimulatory molecules (12) , and among these, TL1A and OX40L were proved to contribute to dectin-1-activated DC-induced Th9 cell priming (12) . However, the role of the other cytokines in dectin-1-activated DC-induced Th9 cell differentiation and antitumor efficacy remains unclear.
Il33, the gene encoding IL-33, is the third highest expressed gene among the 42 upregulated cytokine and costimulatory molecule genes in dectin-1-activated DCs (12) . IL-33 is a member of the IL-1 superfamily cytokines and a ligand for IL-1 receptor-like 1 (IL1RL1, also known as ST2) (23, 24) . IL-33 has been reported to be implicated in multiple allergic disorders by stimulating Th2-associated cell responses (25) . In cancer immunology, IL-33 inhibits tumor growth through activation of CD8 + T and NK cells (26, 27) . IL-33 enhances the intratumor accumulation of type 2 innate lymphoid cells and eosinophils, which mediate potent antitumor activity (28, 29) . IL-33 can also promote the antitumor immunity by restoring the activation and maturation of DCs and inhibiting the differentiation and function of granulocytic myeloid-derived suppressor cells in tumors (30, 31) . IL-33 stimulates DC expression of OX40L (25) , which may favor the induction of Th9 cells (12, 15) . Recently, Ramadan et al. showed that IL-33-treated IL-9-producing T (T9) cells have more potent antileukemic capacity than untreated T9 cells (32) . Based on these observations, we hypothesized that IL-33 would greatly contribute to dectin-1-activated DC-induced Th9 cell differentiation and antitumor efficacy.
In this study, we showed that dectin-1 activation stimulates IL-33 expression in DCs. We found that IL-33 contributes to dectin-1-activated DC-induced Th9 cell differentiation. More importantly, the addition of IL-33 further promotes dectin-1-activated DC induction of Th9 cells and antitumor efficacy. Our results demonstrate the important role of IL-33 in dectin-1-activated DC-induced antitumor immunity and may have important clinical implications.
MaTerials anD MeThODs
Mice and cell lines C57BL/6, OT-II [C57BL/6 − Tg(TcraTcrb)425Cbn/J], and Balb/c mice were purchased from the Jackson Laboratory. Phenotype of OT-II transgenic mice was examined and confirmed (Figures S1A,B in Supplementary Material). Dectin-1 −/− mice were provided by G. Brown (University of Aberdeen, Aberdeen, Scotland). All mice were housed and bred under specific pathogenfree conditions at Animal Center of The First Hospital of Jilin University. Mice were used for experiments at age 6-8 weeks. All animal studies were conducted according to the ethical guidelines of the Animal Ethical Committee of First Hospital of Jilin University.
B16, B16-OVA, and MPC-11 were purchased from ATCC (Rockville, MD, USA). Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone), 100 U/mL penicillin (Hyclone), and 100 mg/mL streptomycin (Hyclone). Cells were grown in standard (37°C, 5% CO2) culture incubators.
reagents and antibodies (abs)
Recombinant mouse GM-CSF, TNF-α, IL-1β, and IL-4 were purchased from Peprotech. Recombinant mouse IL-33 and human TGF-β were purchased from R&D Systems. OVA (323-339, ISQ AVH AAH AEI NEA GR) peptide used in OT-II mouse model and TRP-1 (106-130, SGH NCG TCR PGW RGA ACN QKI LTV R) peptide were purchased from GL Biochem (Shanghai) Ltd. Functional anti-mouse CD3e and CD28 antibodies (mAbs) were purchased from eBioscience. ST2-blocking mAb (αST2), IL-33 neutralization mAb (αIL33), IL-9 neutralization mAb (αIL9), and control IgG were purchased from R&D Systems. Curdlan and Scleroglucan were purchased from Sigma-Aldrich and Invivogen, respectively.
generation of Dcs
Dendritic cells were generated as described previously (12) . In brief, bone marrow cells were cultured in RPMI 1640 complete medium supplemented with GM-CSF (20 ng/mL) and IL-4 (10 ng/mL). At day 4, the culture medium was replaced with fresh GM-CSF (10 ng/mL) and IL-4 (10 ng/mL)-containing medium. At day 7, the semi-adherent cells were collected as immature DCs (iDCs) and matured by TNF-α (10 ng/mL) and IL-1β (10 ng/mL) (BMDCs), Curdlan (5 µg/mL, CurDCs) or Scleroglucan (10 µg/mL, SclDCs) for 48 h. At day 9, the semiadherent cells were collected as mature DCs (mDCs) for further experiments.
In some experiments, iDCs were generated from wildtype (WT) and Dectin-1 −/− C57BL/6 mice and matured with TNF-α/IL-1β (BMDCs), Curdlan (CurDCs), or Scleroglucan (SclDCs) for 2 days. mDCs were analyzed for IL-33 gene expression by flow cytometry, quantitative polymerase chain reaction (qPCR), and enzyme-linked immunosorbent assay (ELISA).
gene expression Profiling Data
Microarray analyses of the gene expression profiles of BMDCs and CurDCs were performed previously (12) . Data are stored in the GEO repository and is accessible under the accession number GSE81111.
Flow cytometry analysis
Immunofluorescence surface staining was performed as previously described (12) . The fluorescence-labeled mAbs against CD3, CD4, CD25, CD62L, and PD-1 were purchased from BD Biosciences; APC-labeled ST2 Ab was purchased from BioLegend. PE labeled anti-mouse TCR Vβ5.1, 5.2 (139504, clone MR9-4) was purchased from BioLegend.
Intracellular staining was performed as previously described (12) . PE-or Pacific Blue-conjugated mAbs against IL-9, IFN-γ, IL-17, GzmB, Foxp3, and Ki67 were purchased from BioLegend. After staining, cell samples were analyzed by a BD LSRFortessa™ cytometer.
In Vitro Th9 cell Differentiation
Naïve CD4
+ T cells (CD4
) were purified by fluorescence activated cell sorter (FACS) from mouse spleens and cocultured at 1 × 10 5 per well with BMDCs or CurDCs (1 × 10 5 / well) in the presence of plate-bound anti-CD3 (2 µg/mL) plus TGF-β (3 ng/mL) and IL-4 (10 ng/mL). Cells from cultures without addition of TGF-β and IL-4 were used as Th0 cells. In some cell cultures, αST2 (5 µg/mL) or IL-33 (50 ng/mL) were added. After 3 days of culture, cells were harvested and analyzed by flow cytometry and/or qPCR.
In Vitro regulatory T (Treg) cell Differentiation

Naïve CD4
+ T cells were isolated from mouse spleens by FACS and cocultured at 1 × 10 5 per well with BMDCs or CurDCs (1 × 10 5 /well) in the presence of plate-bound anti-CD3 (2 µg/mL) and soluble anti-CD28 (2 µg/mL) plus TGF-β (3 ng/mL). In some cell cultures, IL-33 (50 ng/mL) was added. After 3 days of culture, cells were harvested and analyzed by qPCR.
Quantitative Polymerase chain reaction
Total RNA was extracted from cells using an EasyPure RNA Kit (TransGen Biotech), and cDNA was synthesized with an All-in-One First-Strand cDNA Synthesis SuperMix (TransGen). The mRNA levels of Foxp3, Ifng, Il2, Il9, Il17, Il33, Irf4, Gzmb, Pdcd1, Prf1, and St2 (gene for the transmembrane form, ST2L) by DCs or Th cells were analyzed. Expression was normalized to the expression of the housekeeping gene Gapdh. Primer sets for Foxp3, Ifng, Il9, Il17, and Irf4 were shown in the previous publication (12) . Primer sets for Il2, Il33, Gzmb, Pdcd1, Prf1, and St2 are listed in Table S1 in Supplementary Material.
enzyme-linked immunosorbent assay
Concentrations of IL-33, IL-9, and IFN-γ in culture supernatants were detected by ELISAs as previously described (12) . IL-33 capture/detection Abs were purchased from R&D Systems. Recombinant mouse IL-33 (aa109-266) (ELISA standard) was purchased from R&D Systems. Capture/detection Abs for IL-9 and IFN-γ were purchased from BD Biosciences. Recombinant mouse IL-9 and IFN-γ used as the standards in ELISAs were purchased from R&D Systems and BD Biosciences, respectively. Avidin-HRP was purchased from BioLegend.
Tumor immunotherapy experiments
BMDCs and CurDCs were pulsed with OT-II OVA peptides (5 µg/mL) for 2-4 h and then harvested for mouse immunization (n = 4-5/group). B16-OVA (2 × 10 5 cells/mouse) were injected subcutaneously into OT-II mice. On day 3 after tumor challenge, mice were randomly divided into groups and given two weekly subcutaneous immunizations with treated DCs (1 × 10 6 cells/ mouse). Mice injected with PBS served as controls. In some experimental groups, mice were given IL-33 (250 ng/mouse) every 3 days starting at 1 day after the first DC immunization. Tumor volume was calculated by the formula: 3.14 × (mean diameter) 3 /6. Mice were killed when the tumor diameter reached to the range between 1.5 and 2 cm.
We also used MPC-11 myeloma tumor model to further examine the role of dectin-1-activated DCs plus IL-33 in tumor therapy. MPC-11 tumor cells (1 × 10 6 cells/mouse) were injected subcutaneously into Balb/c mice. MPC-11 tumor cell lysates were generated by five rapid freeze-thaw cycles as described previously (33) and were used as tumor antigens. On day 3 after tumor challenge, BMDCs or CurDCs (1 × 10 6 cells/mouse) loaded with tumor cell lysates (100 μg/1 × 10 6 DCs) were used for the tumor treatment in the presence or absence of IL-33. Mice were treated twice (1 week apart). Mice injected with PBS served as controls. Tumor growth was monitored overtime.
In Vivo Functional Tests of il-33/sT2 in Dc-induced T cell Differentiation
BMDCs and CurDCs were pulsed with OT-II OVA peptides (5 µg/mL). Mice were given two weekly subcutaneous immunizations with 1 × 10 6 treated DCs. Mice injected with PBS served as controls. In some experiments, mice were given control IgG or blocking anti-ST2 mAb (αST2, 25 μg/mouse) or IL-33 (250 ng/ mouse) every 3 days starting at 1 day after the first DC immunization. On day 3 after the second DC immunization, total leukocytes from spleens and lymph nodes were restimulated with peptide-pulsed DCs for 24 h. Cells from PBS control mice were cultured without addition of DCs. Culture cells and supernatants were collected and analyzed by qPCR, ELISA, and flow cytometry.
statistical analysis
The Student's t-test (2 groups) and one-way ANOVA (≥3 groups) were used to compare various experimental groups. A P value of less than 0.05 was considered significant. . (e-g) BMDCs, CurDCs, and SclDCs were generated from wild-type (WT) or dectin-1 −/− mice. Same as in (B-D), the mRNA (e) and protein (F,g) levels of IL-33 expressed by DCs were analyzed by qPCR, ELISA, and intracellular staining separately. The experiments were performed three times (n = 3). Results shown are the mean ± SD of three (B-g) independent experiments. *P < 0.05; **P < 0.01. 
il-33 contributes to Dectin-1-activated Dc-induced Th9 Differentiation
Dectin-1-activated DCs potently promote Th9 cell differentiation in vitro and in vivo (12) . To determine the role of IL-33 in dectin-1-activated DC-induced Th9 cell differentiation, a blocking antibody against ST2 (αST2) was used. Naïve CD4 + T cells were cocultured with CurDCs under Th9-polarizing conditions with or without the addition of αST2. αST2 treatment moderately decreased CurDC-induced Th9 cell development (Figures 2A,B) and IL-9 expression (Figures 2A-C) and slightly inhibited the expression of Th9-related transcription factor Irf4 ( Figure 2D ) in CurDC-induced Th9 cells as compared to untreated controls; whereas αST2 treatment did not affect BMDC-induced Th9 cell development (Figures 2A,B) and Il9 ( Figure 2C ) and Irf4 ( Figure 2D ) expression in BMDC-induced Th9 cells. Furthermore, αST2 treatment did not alter Il13 expression in CurDC-induced Th9 cells ( Figure 2C ). These results indicated that IL-33 partially mediates dectin-1-activated DC-induced Th9 cell differentiation.
To further explore the effects of IL-33 on dectin-1-activated DC-induced Th9 cell differentiation, cytokine IL-33 was added during Th9 induction by CurDCs. The addition of IL-33 further stimulated CurDC-induced Th9 cell development (Figures 2A,B) and increased IL-9 (Figures 2A-C OVA-peptide-pulsed BMDCs and CurDCs. CurDC-treated mice had higher percentages of ST2-expressing CD4 + (ST2 + CD4 + ) T cells in spleen cells ( Figure 3A ) and higher levels of St2 mRNA expression in CD4 + T cells ( Figure 3B ) than mice treated with BMDCs or PBS controls. However, there was no difference in ST2 expression by CD4 + T cells from mice immunized with BMDCs compared to PBS controls (Figures 3A,B) . In addition, the immunization of CurDCs compared to BMDCs or PBS control also led to higher frequencies of ST2 + CD4 + T cells in C57BL/6 mouse model ( Figures S4A,B Figures 3C,D) . Together, these data demonstrated that IL-33/ST2 axis contributed to dectin-1-activated DC induction of Th9 and Th1 cells in vivo.
We Figures 3E,F) . ELISA and/or qPCR further confirmed the increased expression of IL-9, IFN-γ, and Gzmb in mice immunized with CurDCs plus IL-33 compared with CurDCs or BMDCs plus IL-33 ( Figures 3G,H) . Interestingly, Th cells treated with CurDCs plus IL-33 expressed higher levels of ST2 than these treated with CurDCs or BMDCs plus IL-33 both in vivo (Figures 3E,F,H) and in vitro (Figure 2E) .
Lymphocyte infiltration in tumors plays a central role in mediating the antitumor effects induced by DC-based tumor therapy. We next analyzed the tumor-infiltrating lymphocytes (TILs) in B16-OVA tumor-bearing OT-II mice immunized with CurDCs plus IL-33. As shown in Figures S6A,B + T cells. The experiments were performed three times (n = 3). Data are representative of three (a,e) independent experiments or presented as mean ± SD of three (a-D,F-h) independent experiments. NS, non-significant; *P < 0.05; **P < 0.01. 6 MPC-11 cells. On day 3 after tumor challenge, mice (five mice/group) were given two weekly subcutaneously immunizations with 1 × 10 6 tumor cell lysate-pulsed BMDCs or CurDCs. Some mice were given IL-33 every 3 days, beginning on the day of the first immunization. Mice that received PBS served as controls. Shown are the tumor growth curves. The experiments were performed twice with a total of 10 mice per group (n = 10). Results shown are the mean ± SD of two combined experiments. **P < 0.01. + T cells. The experiments were performed three times (n = 3). Data are representative of three (a) independent experiments or presented as mean ± SD of three (a-D) independent experiments. NS, non-significant; *P < 0.05; **P < 0.01. 
DiscUssiOn
Tumor-specific Th9 cells are potent antitumor effector cells (10, 11) . We recently reported that dectin-1-activated DCs promote Th9 cell differentiation and trigger potent therapeutic effects against established tumors, better than regular BMDCs (12, 13) . However, mechanisms underlying the induction of Th9 cells and antitumor efficacy by dectin-1-activated DCs are not fully defined. IL-33 is one of the 42 upregulated genes of cytokines and costimulatory molecules in dectin-1-activated DCs (12). And we also confirmed the upregulation of IL-33 expression in dectin-1-activated DCs in this study. However, the role of IL-33 in the induction of Th9 cells and antitumor immunity by dectin-1-activated DCs still remains unknown. IL-33 is a nuclear cytokine, which is released via cell necrosis (36) . Matured DCs will undergo cell death in vitro and in vivo and IL-33 can be released from these dying dectin-1-activated DCs, which may affect T cell differentiation primed by dectin-1-activated DCs. Indeed, in this study, we found that blocking IL-33/ST2 axis inhibits dectin-1-activated DC-induced Th9 differentiation in vitro and in vivo. In addition, the addition of IL-33 further promotes the development of Th9 and Th1 cells induced by dectin-1-activated DCs. More importantly, the addition of IL-33 further increases dectin-1-activated DC-induced antitumor efficacy in mouse models. Consistently, a recent report showed that IL-33-treated IL-9-producing T cells have higher antileukemic capabilities than untreated cells (32) . Thus, our data demonstrate the important role of IL-33 in dectin-1-activated DC-induced Th9 cell differentiation and antitumor efficacy.
Cytokine milieu is the major determinant for Th cell differentiation (5, 37) . The cytokine IL-33 itself may promote the differentiation of Th1 or Th9 cells, depending on the cytokine milieu (24, 32) . Regular matured DCs express high levels of IL-12, a key cytokine for Th1 cell differentiation (38) , which along with IL-33 directs naïve CD4 + T cells to differentiate into Th1 cells. However, dectin-1-activated DCs produce large amounts of TNF superfamily cytokines, such as TNFSF15 and OX40L (12, 14, 15) , which along with IL-33 may further promote Th9 cell formation. Th1 cells are terminally differentiated, shorter lived effector cells (39, 40) , however, Th9-derived IL-9 has the potential to enhance the survival and proliferation of T cells (12) . In addition, IL-33 itself may stimulate the survival and proliferation of T cells (41) . Thus, these observations may account for the capability of IL-33 in promoting Th9 cell production and antitumor immunity in dectin-1-activated DC-immunized mice but not in BMDCimmunized mice.
In this study, we found that IL-33 increases the production of Foxp3 + Treg cells in mice immunized by BMDCs but not dectin-1-activated DCs. Treg cells can be divided into naturally occurring (nTreg) and inducible (iTreg) regulatory cells (42) . nTreg cells are generated in the thymus and are 5-10% of the total peripheral CD4 + T cells (43) . By contrast, iTregs are peripherally induced from naive CD4 + T cells in response to foreign antigens in the presence of TGF-β1 (44, 45) . These observations suggest that IL-33 increases the production of iTreg but not nTreg cells in BMDC-immunized mice. It remains unclear about mechanisms of the different function roles of IL-33 in Treg cell differentiation in BMDC-and dectin-1-activated DC-immunized mice. But dectin-1-activated DCs overexpress the TNF family cytokines TNF-α, TNFSF15 (TL1A), OX40L, and TNFSF8 (12, 13) . Among these cytokines, OX40L inhibits Treg cell differentiation and TL1A inhibits the immunosuppressive function of Treg cells (46) (47) (48) (49) . Based on these observations, we speculate that the specific profile of cytokines and costimulatory molecules expressed by dectin-1-activated DCs, especially OX40L and TL1A may contribute to the inhibition of Treg cell differentiation induced by IL-33.
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